Steven Paget

Director, Head of Medicinal Chemistry @Aprinoia Therapeutics

Cambridge, MA, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Jan 2025 — Present

Director, Head of Medicinal Chemistry @Aprinoia Therapeutics

View department →

Cambridge, MA, US

EDUCATION

1987 — 1991

Cornell University

Bachelor of Arts (B.A.), Chemistry

1991 — 1997

The Ohio State University

Doctor of Philosophy (Ph.D.), Organic Chemistry

SKILLS

HplcOrganic ChemistryNmrMedicinal ChemistryLead ChangeDmpkDrug DiscoveryOrganic SynthesisAdmePurificationDrug DesignChemistry

ABOUT STEVEN PAGET

Notable Accomplishments:• Novel STING agonist development candidate identified (Venenum Biodesign)• Discovered and developed RWJ-416457, an antimicrobial agent evaluated in First-in-Human /Phase I clinical trials (Janssen Pharmaceuticals)• Oncology development candidate identified for BMI1(PTC Therapeutics/Wellcome Trust)• Antiviral development candidate identified for Hepatitis C (PTC Therapeutics/Merck)

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Steven Paget — Director, Head of Medicinal Chemistry at Aprinoia Therapeutics in Cambridge, MA, US | Unifers